Literature DB >> 28045749

Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.

Shaun Chou1, Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, Pablo Fernandez-Penas.   

Abstract

Lichenoid drug reaction is a common adverse reaction in patients taking immune-modulatory agents such as antiprogramed cell death (PD-1) and cytotoxic T lymphocyte antigen-4 agents. The authors describe the clinical and histologic features of lichenoid drug reaction in 20 biopsies from 15 patients on anti-PD-1 agents and 9 biopsies from 7 patients on anti-PD-1 plus ipilimumab therapy. Clinically, all except 2 patients presented with discrete, violaceous exanthematous papules to plaques. The lichenoid inflammation in the majority (18 of 29 biopsies) was florid although histology was quite heterogeneous. Nevertheless, there was frequent involvement of the superficial follicular epithelium and acrosyringium, and also a propensity to blister that occurred in approximately 20% of the biopsies. Occasional patients had disease closely resembling lichen planus, although all of these biopsies had some atypical features for lichen planus such as parakeratosis. Dermal eosinophils were common particularly in those with mild inflammation. The lichenoid reaction was responsive to topical steroid or oral systemic treatment in general, and the anti-PD-1 agent had to be ceased in only one patient.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28045749     DOI: 10.1097/DAD.0000000000000587

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  10 in total

Review 1.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

2.  Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Authors:  Genevieve J Kaunitz; Manisha Loss; Hira Rizvi; Sowmya Ravi; Jonathan D Cuda; Karen B Bleich; Jessica Esandrio; Inbal Sander; Dung T Le; Luis A Diaz; Julie R Brahmer; Charles G Drake; Travis J Hollmann; Mario E Lacouture; Matthew D Hellmann; Evan J Lipson; Janis M Taube
Journal:  Am J Surg Pathol       Date:  2017-10       Impact factor: 6.394

Review 3.  [Lichenoid drug reactions].

Authors:  H F Merk; L Vanstreels; M Megahed
Journal:  Hautarzt       Date:  2018-02       Impact factor: 0.751

4.  Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.

Authors:  Emma Fixsen; Jigar Patel; Maria Angelica Selim; Meenal Kheterpal
Journal:  Oncologist       Date:  2019-01-07

5.  Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

Authors:  V Sibaud; C Eid; V R Belum; P Combemale; B Barres; L Lamant; L Mourey; C Gomez-Roca; C L Estilo; R Motzer; E Vigarios; M E Lacouture
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-05-08       Impact factor: 6.166

Review 6.  Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

Authors:  Jennifer Choi; Ronald Anderson; Ada Blidner; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas Johnson; Vickie R Shannon; Maria Suarez-Almazor; Bernardo L Rapoport; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2020-08-27       Impact factor: 3.603

Review 7.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

Review 8.  Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.

Authors:  Megan H Trager; Donatienne de Clippelé; Caroline Ram-Wolff; Adèle de Masson; Marie-Dominique Vignon-Pennamen; Maxime Battistella; Laurence Michel; Martine Bagot; Gabor Dobos
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

Review 9.  Adnexotropic Variants of the Interface Dermatitides: A Review.

Authors:  Carla Stephan; Ossama Abbas; Jag Bhawan
Journal:  Dermatopathology (Basel)       Date:  2021-05-21

10.  Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance.

Authors:  Tricia Cottrell; Jiajia Zhang; Boyang Zhang; Genevieve J Kaunitz; Poromendro Burman; Hok-Yee Chan; Franco Verde; Jody E Hooper; Hans Hammers; Mohamad E Allaf; Hongkai Ji; Janis Taube; Kellie N Smith
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.